Reconocimientos y publicaciones científicas
Además de mi actividad clínica como hematólogo, he desarrollado una línea académica enfocada en hematología y oncohematología, con especial interés en mieloma múltiple, gammapatías monoclonales, trasplante autólogo, complicaciones renales, infecciones y genética aplicada a enfermedades hematológicas.
Mi participación en publicaciones científicas, congresos y reconocimientos internacionales refleja un compromiso constante con la medicina basada en evidencia y la actualización continua.
Premios
IMS Young Investigator Award for Exemplary Abstract, 21th International Myeloma Workshop, International Myeloma Society. (2024)
IMS Young Investigator Award for Exemplary Abstract, 18th International Myeloma Workshop, International Myeloma Society. (2021
IMS Career Development Award.
International Myeloma Society. 2023
IMS Career Development Award.
International Myeloma Society. 2022
Clinical Research Training Institute in Latin America (CRTI-LA), American Society of Hematology. (2020).
EHA master class. European Hematology Association (2022)
International Academy for Clinical Hematology, Young Ambassador program (2023).
Mi producción científica se ha enfocado principalmente en mieloma múltiple, gammapatías monoclonales, trasplante autólogo, complicaciones renales, infecciones, genética, trasplante renal y resultados clínicos en hematología.
A continuación, se presentan algunas publicaciones representativas de esta trayectoria académica:
Single-nucleotide variants as potential prognostic biomarkers in newly diagnosed multiple myeloma patients. Hematology, Transfusion and Cell Therapy, 2026.
Screening for monoclonal gammopathies in the adult population of Uruguay. Blood Global Hematology, 2026.
Dara-VRd o Dara-Rd en primera línea en pacientes con mieloma no elegibles a trasplante. Una reflexión acerca de los estudios MAIA y CEPHEUS. Revista de Hematología México, 2026.
Characteristics and Outcomes of Multiple Myeloma Patients with Post-Transplant Relapse: A Latin American Real-World Cohort Study. Clinical Lymphoma, Myeloma & Leukemia, 2025.
Propensity Score–Weighted Comparison of Daratumumab-Rd versus Daratumumab-VMP, Rd, and VMP in High-Risk Multiple Myeloma: Insights from the MAIA and ALCYONE Trials. Clinical Lymphoma, Myeloma & Leukemia, 2025.
Propensity Score–Matched Comparison of Daratumumab-Rd versus Daratumumab-VMP in Transplant-Ineligible Multiple Myeloma Patients with del(17p13): An Analysis of the MAIA and ALCYONE Trials. Clinical Lymphoma, Myeloma & Leukemia, 2025.
Survival of Patients with Multiple Myeloma Treated with Bortezomib-Based Triplets and Autologous Hematopoietic Stem Cell Transplant As First Line in Latin America. Blood, 2023.
Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay. Hematology, Transfusion and Cell Therapy, 2023.
Free light chain ratio over 100 and risk of hemodialysis in multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia, 2023.
Evaluation of single nucleotide variants in BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cell transplantation: association with clinical outcomes. Clinical Lymphoma, Myeloma & Leukemia, 2023.
Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting. Acta Medica, 2023.
Survival analysis of transplant-eligible newly diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting. Current Problems in Cancer, 2023.
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis. Journal of Oncology Pharmacy Practice, 2022.
Evaluation of single nucleotide variants of CDKN1A, TP53BP, and XRCC1 genes in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with treatment response. Clinical Lymphoma, Myeloma & Leukemia, 2022.
Prevalence of monoclonal gammopathies in adult Uruguayan population. Clinical Lymphoma, Myeloma & Leukemia, 2022.
Salvage autologous stem cells transplantation and maintenance therapy in relapsed refractory multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia, 2021.
Effect of induction regimen in survival in newly diagnosed multiple myeloma patients receiving consolidation with autologous stem cell transplantation. Clinical Lymphoma, Myeloma & Leukemia, 2021.
Spinal cord compression due to a solitary, bulky plasmacytoma of posterior mediastinum. Radiology Case Reports, 2021.
Comparative survival analysis using the International Stratification Score in newly diagnosed multiple myeloma in the Uruguayan population. Medicine and Pharmacy Reports, 2021.
Prevention of Bortezomib-Induced Polyneuropathy in Multiple Myeloma Patients. Journal of Hematology Research, 2020.
Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. Hematology, Transfusion and Cell Therapy, 2020.
Limitaciones en el manejo de mieloma múltiple en Ecuador. Revista de la Facultad de Ciencias Médicas, 2020.